Medications for Breakthrough Pain

3 results
ProStrakan, Inc.
Usage: ABSTRAL (fentanyl) sublingual tablets are indicated for managing breakthrough pain in cancer patients aged 18 and older who are opioid tolerant. It is contraindicated for non-tolerant patients and for acute pain management. Prescribing is restricted to knowledgeable healthcare professionals under the TIRF REMS Access program.

Actiq (fentanyl citrate)

(Fentanyl Citrate)
Cephalon, LLC
Usage: ACTIQ is indicated for managing breakthrough pain in cancer patients aged 16 and older who are already tolerant to around-the-clock opioid therapy for persistent cancer pain. It is not for use in opioid non-tolerant patients or for acute or postoperative pain management.

Lazanda (fentanyl citrate)

(Fentanyl Citrate)
Archimedes Pharma US Inc.
Usage: Lazanda (fentanyl) nasal spray is indicated for managing breakthrough cancer pain in opioid-tolerant patients aged 18 and older. It is not intended for acute pain management and must be prescribed by qualified healthcare professionals. Patients need to maintain ongoing opioid use while using Lazanda.